Form 4: Organon & Co. Executive Joseph T. Morrissey, Jr. Reports Stock Option Grant and RSU Vesting

Joseph T. Morrissey, Jr., Head of Manufacturing at Organon & Co., reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

Summary

• On March 31, 2025, Joseph T. Morrissey, Jr., Head of Manufacturing at Organon & Co., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The filing reports the vesting of several tranches of Restricted Stock Units (RSUs) awarded in previous years, specifically on March 31, 2022, March 31, 2023 and March 29, 2024.
• These vestings resulted in the acquisition of 9,751, 7,795 and 3,937 shares of common stock, respectively.
• The filing also reports the grant of 50,369 new RSUs and 247,524 stock options, which vest in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
• Additionally, the filing indicates the disposition of shares to cover tax obligations related to the RSU vesting, with 4,241, 3,391 and 1,713 shares disposed of at a price of $14.51.
• Following these transactions, Morrissey directly owns 71,561.855 shares of Organon & Co. common stock, 247,524 stock options and 50,369 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of stock transactions by an executive. While the grant of equity can be seen as positive, the tax-related disposals are neutral.

Positives

• The grant of stock options and RSUs to a key executive like the Head of Manufacturing can be seen as a positive sign, aligning their interests with the long-term success of the company.
• The vesting of RSUs indicates that the executive has met certain performance or time-based requirements, which could be interpreted as a positive contribution to the company.

Negatives

• The disposition of shares to cover tax obligations, while a normal occurrence, slightly reduces the executive's direct ownership in the company.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, any significant decrease in the company's stock price could impact the value of the executive's stock options and RSUs, potentially affecting their motivation.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a continued commitment to the company by the executive over the next three years.

Industry Context

This type of filing is standard for publicly traded companies and provides transparency into the compensation and ownership structure of key executives. It's common for pharmaceutical companies like Organon to use stock options and RSUs as part of their compensation packages to incentivize performance and retain talent.

Comparison to Industry Standards

• Stock option and RSU grants are a common practice among publicly traded pharmaceutical companies to align executive compensation with company performance.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
• The vesting schedules (three equal installments over three years) are fairly standard in the industry.
• The specific number of shares and option grants would be benchmarked against companies of similar size and market capitalization within the pharmaceutical sector.

Stakeholder Impact

• The transactions reported in this filing have a minimal direct impact on stakeholders.
• Shareholders may view the equity grants as a positive sign of aligning management interests with company performance.
• Employees may see the executive's continued investment in the company as a sign of confidence.

Key Dates

Keywords

Organon & Co., Joseph T. Morrissey Jr., Form 4, RSU, Stock Options, Beneficial Ownership, Vesting, Head of Manufacturing